glp-1 science The journey: from discovery to therapeutic impact The GLP-1 boom: Challenges, trends,

PCOS Sisters focuses on long-term strategies that may include: metabolic support medications, insulin-targeted therapies, & hormone-informed maintenance plans GLP-1 treatment at PCOS Sisters is often incorporated into our broader evidence backed metabolic program

Semaglutide in SUSTAIN-6 trial reduced the risk of MACE by 26% in patients with T2D, mostly by reducing rate of nonfatal stroke (39%) compared to placebo

A healthy diet that is low in calories and high in protein and fiber can help increase satiety and reduce calorie intake

The CVOTs provide additional evidence for cardiovascular risk reduction with GLP-1RAs in patients with T2D

Many patients transition to a lower maintenance dose over time

GLP-1 medications can produce rapid weight reduction that outpaces the skins ability to adjust, creating more pronounced laxity